PL1904082T3 - PROCEDURA OZNACZANIA STĘŻENIA ADIPOCYTOWEJ FORMY BIAŁKA WIĄŻĄCEGO KWASY TŁUSZCZOWE (A-FABP, FABP4, aP2) - Google Patents

PROCEDURA OZNACZANIA STĘŻENIA ADIPOCYTOWEJ FORMY BIAŁKA WIĄŻĄCEGO KWASY TŁUSZCZOWE (A-FABP, FABP4, aP2)

Info

Publication number
PL1904082T3
PL1904082T3 PL06795383T PL06795383T PL1904082T3 PL 1904082 T3 PL1904082 T3 PL 1904082T3 PL 06795383 T PL06795383 T PL 06795383T PL 06795383 T PL06795383 T PL 06795383T PL 1904082 T3 PL1904082 T3 PL 1904082T3
Authority
PL
Poland
Prior art keywords
fabp
fatty acid
adipocytic
concentration
binding protein
Prior art date
Application number
PL06795383T
Other languages
English (en)
Inventor
Viktor Ruzicka
Original Assignee
Biovendor Laboratory Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovendor Laboratory Medicine Inc filed Critical Biovendor Laboratory Medicine Inc
Publication of PL1904082T3 publication Critical patent/PL1904082T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
PL06795383T 2005-07-21 2006-07-21 PROCEDURA OZNACZANIA STĘŻENIA ADIPOCYTOWEJ FORMY BIAŁKA WIĄŻĄCEGO KWASY TŁUSZCZOWE (A-FABP, FABP4, aP2) PL1904082T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005034788 2005-07-21
EP06795383A EP1904082B1 (de) 2005-07-21 2006-07-21 VERFAHREN ZUR BESTIMMUNG DER KONZENTRATION DER ADIPOZYTAREN FORM DES FATTY ACID BINDUNG PROTEIN (A-FABP, FABP4, aP2)
PCT/IB2006/002383 WO2007063363A2 (de) 2005-07-21 2006-07-21 Verfahren zur bestimmung der konzentration der adipozytären form des fatty acid binding protein (a-fabp, fabp4, ap2)

Publications (1)

Publication Number Publication Date
PL1904082T3 true PL1904082T3 (pl) 2010-12-31

Family

ID=38048068

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06795383T PL1904082T3 (pl) 2005-07-21 2006-07-21 PROCEDURA OZNACZANIA STĘŻENIA ADIPOCYTOWEJ FORMY BIAŁKA WIĄŻĄCEGO KWASY TŁUSZCZOWE (A-FABP, FABP4, aP2)

Country Status (9)

Country Link
US (2) US8846413B2 (pl)
EP (1) EP1904082B1 (pl)
JP (1) JP5222138B2 (pl)
AT (1) ATE468128T1 (pl)
AU (1) AU2006321321B2 (pl)
CA (1) CA2614340A1 (pl)
DE (1) DE502006006990D1 (pl)
PL (1) PL1904082T3 (pl)
WO (1) WO2007063363A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090311729A1 (en) * 2006-03-22 2009-12-17 Dainippon Sumitomo Pharma Co., Ltd Diagnosis of acute enterocolitis by determination of intestinal fatty acid-binding protein in the blood
EP2403605B1 (en) 2009-03-05 2015-05-06 President and Fellows of Harvard College Compositions comprising an aP2-specific antibody or a fragment thereof for use in treating diabetes, glucose intolerance or obesity-induced insulin resistance
EP2392927A1 (en) * 2011-03-11 2011-12-07 F. Hoffmann-La Roche AG Diagnosis of metabolic disorders in HIV infected patients
CZ304067B6 (cs) 2011-11-11 2013-09-18 Biovendor - Laboratorní Medicína A.S. Metoda pro stanovení koncentrace uromodulinu v séru a jeho pouzití jako sérového markeru pro diagnózu nefropatie
US20150309053A1 (en) * 2012-10-23 2015-10-29 Riken Test method and test kit for psychiatric ailments
KR101834857B1 (ko) * 2015-01-05 2018-03-07 서울대학교산학협력단 제2형 당뇨병의 조기 진단을 위한 단백질 바이오 마커
AU2016254215A1 (en) 2015-04-30 2017-10-26 President And Fellows Of Harvard College Anti-aP2 antibodies and antigen binding agents to treat metabolic disorders
JP6558729B2 (ja) * 2015-06-15 2019-08-14 北海道公立大学法人 札幌医科大学 糸球体障害の検査方法
AU2018279950A1 (en) 2017-06-09 2020-01-30 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
CN112744118B (zh) * 2019-10-31 2022-12-09 比亚迪股份有限公司 电池管理系统、方法与车辆

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066784A2 (en) * 1999-05-05 2000-11-09 Ohio University Growth hormone-regulatable brown adipose tissue genes, corresponding proteins and uses thereof
US7371563B2 (en) * 2000-11-08 2008-05-13 Surface Logix, Inc. Peelable and resealable devices for biochemical assays
JP2004065194A (ja) * 2002-08-09 2004-03-04 Sumitomo Chem Co Ltd 脂肪細胞関連因子の分析方法
JP4611025B2 (ja) * 2002-11-04 2011-01-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 体内のブドウ糖または脂肪酸の代謝に関する高処理量測定のための重水素化ブドウ糖または脂肪の耐性試験
EP2357477B1 (en) * 2003-09-20 2017-11-08 Electrophoretics Limited Diagnostic method for brain damage-related disorders based on the detection of NDKA
AU2004282754B9 (en) * 2003-10-15 2009-12-10 Sekisui Medical Co., Ltd. Method of selectively assaying adiponectin multimer
JP4869942B2 (ja) * 2003-12-11 2012-02-08 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド インスリン感受性／抵抗性、糖尿病および肥満におけるｒｂｐ４
WO2005116189A2 (en) * 2004-05-06 2005-12-08 The Trustees Of The University Of Pennsylvania Compositions and use of inflammation-20 (inf-20) gene

Also Published As

Publication number Publication date
EP1904082B1 (de) 2010-05-19
US20150093769A1 (en) 2015-04-02
ATE468128T1 (de) 2010-06-15
US20090181886A1 (en) 2009-07-16
WO2007063363A2 (de) 2007-06-07
EP1904082A2 (de) 2008-04-02
AU2006321321B2 (en) 2011-07-28
AU2006321321A1 (en) 2007-06-07
DE502006006990D1 (de) 2010-07-01
WO2007063363A3 (de) 2007-08-30
JP2009501926A (ja) 2009-01-22
US8846413B2 (en) 2014-09-30
CA2614340A1 (en) 2007-06-07
JP5222138B2 (ja) 2013-06-26

Similar Documents

Publication Publication Date Title
PL1904082T3 (pl) PROCEDURA OZNACZANIA STĘŻENIA ADIPOCYTOWEJ FORMY BIAŁKA WIĄŻĄCEGO KWASY TŁUSZCZOWE (A-FABP, FABP4, aP2)
de Araújo et al. Nutritional parameters and mortality in incident hemodialysis patients
Fiorentino et al. One-hour postload hyperglycemia is a stronger predictor of type 2 diabetes than impaired fasting glucose
Campos et al. Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels
Stamler et al. Inverse relation of dietary protein markers with blood pressure: findings for 10 020 men and women in the INTERSALT study
Leung et al. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease
Antonisamy et al. Weight gain and height growth during infancy, childhood, and adolescence as predictors of adult cardiovascular risk
Larsson et al. Responses of algesic and metabolic substances to 8 h of repetitive manual work in myalgic human trapezius muscle
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
WO2009077864A3 (en) Compositions and methods of detecting tiabs
Baria et al. Activity-related energy expenditure of patients undergoing hemodialysis
Malin et al. Impact of short-term exercise training intensity on β-cell function in older obese adults with prediabetes
Rajappa et al. Relationship of raised serum total and protein bound sialic acid levels with hyperinsulinemia and indices of insulin sensitivity and insulin resistance in non-diabetic normotensive obese subjects
Zheng et al. Gender differences in the relationship between plasma lipids and fasting plasma glucose in non-diabetic urban Chinese population: a cross-section study
Taguchi et al. Serum folate, total homocysteine levels and methylenetetrahydrofolate reductase 677C> T polymorphism in young healthy female Japanese
Koike et al. Raised homocysteine and low folate and vitamin B-12 concentrations predict cognitive decline in community-dwelling older Japanese adults
JP2007114170A (ja) 疲労度評価方法およびその利用
Gundapaneni et al. Oxidative stress markers in coronary artery disease patients with diabetes mellitus
Lim et al. Adherence to lifestyle recommendations is associated with improved glycemic control and improved blood lipid levels in Korean adults with type 2 diabetes
EP1773762A4 (en) METHODS AND COMPOUNDS FOR DETECTING MEDICAL DISORDERS
Liu et al. Methylenetetrahydrofolate reductase polymorphism determines the plasma homocysteine-lowering effect of large-dose folic acid supplementation in patients with cardiovascular disease
Sharma et al. Interrelationship of elevated serum Advanced Glycation End-product levels and malnutrition (Subjective Global Assessment) scores with the severity of retinopathy in type II diabetes
Iova et al. Oxidative stress in Alzheimer’s dementia
Shiowatana et al. Enhancement effect study of some organic acids on the calcium availability of vegetables: application of the dynamic in vitro simulated gastrointestinal digestion method with continuous-flow dialysis
Malaquias et al. Evaluation of puberty in patients with noonan syndrome and mutations in the RAS/MAPK genes